Group 1 - The company plans to use part of its temporarily idle raised funds for cash management, specifically 80 million RMB, to purchase large-denomination certificates of deposit from China Merchants Bank [2][5][10] - The cash management aims to improve the efficiency of temporarily idle funds, reduce financial costs, and increase shareholder returns while ensuring that it does not affect the construction of investment projects and the company's normal operations [4][16] - The company has approved a total of 700 million RMB for cash management, with the latest approval allowing for an additional 500 million RMB, which can be rolled over within a 12-month period [3][12][11] Group 2 - The source of the funds for cash management comes from the proceeds of convertible bonds issued to unspecified investors, totaling approximately 1.08 billion RMB, net of issuance costs [7][8] - The company has completed the registration and filing procedures for changes in its name and registered capital, with the new registered capital being 1,308,929,289 RMB [19][21] - The company has eliminated its supervisory board, transferring its responsibilities to the audit and risk control committee of the board of directors [19][20]
南京医药集团股份有限公司关于公司及子公司使用部分暂时闲置募集资金进行现金管理的进展公告